时隔8年,欧洲甲状腺协会/欧洲格雷夫斯眼病专家组依据最新循证医学证据,更新了格雷夫斯眼病(Graves orbitopathy,GO)治疗指南。新指南针对GO的评估、治疗进行了全面讨论,仍然强调依据GO严重程度和活动度,以及生活质量(quality of life,Qo L)评分选择治疗方案。新指南有两大新亮点:1对轻度GO患者,推荐6个月的硒补充治疗;2对中重度活动性GO患者,指南明确提出一线、二线治疗方案,强调大剂量糖皮质激素静脉冲击治疗是一线治疗方案。 After a lapse of 8 years, the European Thyroid Association / European Graves Eye Group updates the guidelines for the treatment of Graves orbitopathy (GO) based on the latest evidence-based evidence. The new guidelines provide a comprehensive discussion of the assessment and treatment of GO and continue to emphasize the selection of treatment options based on GO severity and activity, as well as quality of life (QoL) scores. The new guidelines have two new highlights: 1 for mild GO patients, recommended 6 months of selenium supplementation treatment; 2 pairs of moderate to severe GO patients, the guidelines clearly put forward first and second line treatment, emphasizing high-dose glucocorticoid intravenous impact Treatment is the first-line treatment.